Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).
BRAF is a serine/threonine kinase that is mutated in a range of cancers, including 50-70% of melanomas, and has been validated as a therapeutic target. We have designed and synthesized mutant BRAF inhibitors containing pyridoimidazolone as a new hinge-binding scaffold. Compounds have been obtained which have low nanomolar potency for mutant BRAF (12 nM for compound 5i) and low micromolar cellular potency against a mutant BRAF melanoma cell line, WM266.4. The series benefits from very low metabolism, and pharmacokinetics (PK) that can be modulated by methylation of the NH groups of the imidazolone, resulting in compounds with fewer H-donors and a better PK profile. These compounds have great potential in the treatment of mutant BRAF melanomas.
Niculescu-Duvaz
Dan
D
Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Gaulon
Catherine
C
Dijkstra
Harmen P
HP
Niculescu-Duvaz
Ion
I
Zambon
Alfonso
A
Ménard
Delphine
D
Suijkerbuijk
Bart M J M
BM
Nourry
Arnaud
A
Davies
Lawrence
L
Manne
Helen
H
Friedlos
Frank
F
Ogilvie
Lesley
L
Hedley
Douglas
D
Whittaker
Steven
S
Kirk
Ruth
R
Gill
Adrian
A
Taylor
Richard D
RD
Raynaud
Florence I
FI
Moreno-Farre
Javier
J
Marais
Richard
R
Springer
Caroline J
CJ